The Future of Somatostatin Receptor Ligands in Acromegaly.
Acromegaly
/ blood
Antineoplastic Agents, Hormonal
/ administration & dosage
Biomarkers, Tumor
/ blood
Growth Hormone-Secreting Pituitary Adenoma
/ blood
Humans
Octreotide
/ administration & dosage
Peptides, Cyclic
/ administration & dosage
Precision Medicine
/ methods
Quality of Life
Randomized Controlled Trials as Topic
Receptors, Somatostatin
/ metabolism
Somatostatin
/ administration & dosage
Treatment Outcome
acromegaly
biomarker
precision medicine
somatostatin receptor
somatostatin receptor ligands
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
18 01 2022
18 01 2022
Historique:
received:
01
06
2021
pubmed:
8
10
2021
medline:
19
2
2022
entrez:
7
10
2021
Statut:
ppublish
Résumé
Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of patients. Pasireotide, a second-generation SRL, shows higher efficacy with respect to both biochemical control and tumor shrinkage but has a worse safety profile. In this review, we discuss the future perspectives of currently available SRLs, focusing on the use of biomarkers of response and precision medicine, new formulations of these SRLs and new drugs, which are under development. Precision medicine, which is based on biomarkers of response to treatment, will help guide the decision-making process by allowing physicians to choose the appropriate drug for each patient and improving response rates. New formulations of available SRLs, such as oral, subcutaneous depot, and nasal octreotide, may improve patients' adherence to treatment and quality of life since there will be more options available that better suit each patient. Finally, new drugs, such as paltusotine, somatropin, ONO-5788, and ONO-ST-468, may improve treatment adherence and present higher efficacy than currently available drugs.
Identifiants
pubmed: 34618894
pii: 6383448
doi: 10.1210/clinem/dgab726
pmc: PMC8764337
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Biomarkers, Tumor
0
Peptides, Cyclic
0
Receptors, Somatostatin
0
lanreotide
0G3DE8943Y
Somatostatin
51110-01-1
pasireotide
98H1T17066
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
297-308Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.
Références
Endocr Rev. 2004 Feb;25(1):102-52
pubmed: 14769829
Expert Rev Endocrinol Metab. 2007 Mar;2(2):129-145
pubmed: 30754185
Endocrine. 2018 Nov;62(2):448-455
pubmed: 30051198
Endocrine. 2014 Jun;46(2):220-5
pubmed: 24504766
J Clin Endocrinol Metab. 1992 Jul;75(1):163-9
pubmed: 1619006
J Clin Endocrinol Metab. 2021 Jun 16;106(7):2047-2056
pubmed: 33686418
Clin Endocrinol (Oxf). 2008 Mar;68(3):458-65
pubmed: 17941904
J Clin Endocrinol Metab. 2011 May;96(5):1327-35
pubmed: 21325455
Expert Opin Pharmacother. 2013 Dec;14(17):2433-47
pubmed: 24124691
Endocr Relat Cancer. 2013 Sep 16;20(5):753-66
pubmed: 23940012
Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68
pubmed: 17465997
Nat Rev Endocrinol. 2018 Sep;14(9):552-561
pubmed: 30050156
Lancet Diabetes Endocrinol. 2019 Jun;7(6):425-426
pubmed: 30956093
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51
pubmed: 25356808
J Clin Endocrinol Metab. 2020 Oct 1;105(10):
pubmed: 32882036
Pituitary. 2021 Apr;24(2):192-206
pubmed: 33074402
J Clin Endocrinol Metab. 2008 Apr;93(4):1412-7
pubmed: 18211974
J Clin Endocrinol Metab. 2012 Aug;97(8):E1411-20
pubmed: 22659247
J Clin Endocrinol Metab. 2004 Apr;89(4):1577-85
pubmed: 15070915
J Clin Endocrinol Metab. 2012 Jul;97(7):2362-9
pubmed: 22539587
Trends Endocrinol Metab. 2013 May;24(5):238-46
pubmed: 23270713
Pituitary. 2009;12(4):297-303
pubmed: 19330452
J Cell Mol Med. 2021 Mar;25(5):2484-2492
pubmed: 33491286
Life Sci. 1982 Sep 13;31(11):1133-40
pubmed: 6128648
Arq Bras Endocrinol Metabol. 2010 Nov;54(8):698-704
pubmed: 21340155
Endocr Connect. 2019 Apr;8(4):367-377
pubmed: 30851160
Pituitary. 2018 Aug;21(4):335-346
pubmed: 29455389
J Endocrinol Invest. 2004 Sep;27(8):721-7
pubmed: 15636423
J Clin Endocrinol Metab. 2014 Apr;99(4):1282-90
pubmed: 24423301
Clin Endocrinol (Oxf). 2009 May;70(5):757-68
pubmed: 19178516
Orphanet J Rare Dis. 2011 Oct 24;6:67
pubmed: 22024364
Endocr Rev. 2011 Apr;32(2):247-71
pubmed: 21123741
Clin Endocrinol (Oxf). 2015 Jul;83(1):3-14
pubmed: 25640882
Front Neuroendocrinol. 1999 Jul;20(3):157-98
pubmed: 10433861
J Clin Endocrinol Metab. 2020 Jun 1;105(6):
pubmed: 32311048
Hormones (Athens). 2017 Jan;16(1):84-91
pubmed: 28500831
Endocr Connect. 2020 Dec;9(12):1178-1190
pubmed: 33434154
Arch Intern Med. 1991 Aug;151(8):1573-8
pubmed: 1872661
Int J Endocrinol. 2017;2017:9606985
pubmed: 28396686
Endocrinology. 2001 Jan;142(1):477-86
pubmed: 11145612
Eur J Endocrinol. 2012 Feb;166(2):223-34
pubmed: 22065857
Eur J Endocrinol. 2005 Jul;153(1):67-71
pubmed: 15994747
Front Endocrinol (Lausanne). 2021 May 07;12:677919
pubmed: 34025586
Eur J Endocrinol. 2020 Mar;182(3):319-331
pubmed: 31958318
Metabolism. 1992 Sep;41(9 Suppl 2):72-5
pubmed: 1518437
Eur J Endocrinol. 2018 Dec 1;179(6):419-427
pubmed: 30325178
Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84
pubmed: 25260838
Eur J Endocrinol. 2016 Feb;174(2):241-50
pubmed: 26586796
J Clin Endocrinol Metab. 2014 Mar;99(3):791-9
pubmed: 24423324
Endocr Relat Cancer. 2012 May 24;19(3):L25-9
pubmed: 22420004
J Cell Mol Med. 2018 Mar;22(3):1640-1649
pubmed: 29266696
Metabolism. 1992 Sep;41(9 Suppl 2):22-33
pubmed: 1355588
Eur J Endocrinol. 2008 Mar;158(3):295-303
pubmed: 18299461
Ann Oncol. 2006 Dec;17(12):1733-42
pubmed: 16801334
J Clin Endocrinol Metab. 2010 Nov;95(11):E373-83
pubmed: 20685857
J Clin Endocrinol Metab. 2013 Jan;98(1):E66-71
pubmed: 23118420
Front Neuroendocrinol. 2013 Aug;34(3):228-52
pubmed: 23872332
Rev Endocr Metab Disord. 2020 Dec;21(4):667-678
pubmed: 32914330
Drugs. 2016 Sep;76(13):1235-1243
pubmed: 27473537
Endocr Pract. 2019 Apr;25(4):379-393
pubmed: 30657362
Pituitary. 2017 Feb;20(1):109-115
pubmed: 27778296
Br J Clin Pharmacol. 2015 Sep;80(3):460-72
pubmed: 26076191
J Clin Endocrinol Metab. 2020 Sep 1;105(9):
pubmed: 32589751
Endocr Relat Cancer. 2020 Jun;27(6):375-389
pubmed: 32302973
PLoS One. 2012;7(5):e36411
pubmed: 22574156
J Clin Endocrinol Metab. 2017 Jun 1;102(6):2009-2018
pubmed: 28323931
J Endocrinol Invest. 2013 Jan;36(1):38-43
pubmed: 22472799
Eur J Endocrinol. 2020 Jun;182(6):595-605
pubmed: 32375119
J Clin Endocrinol Metab. 2015 Apr;100(4):1699-708
pubmed: 25664604
BMC Endocr Disord. 2020 Jul 31;20(1):117
pubmed: 32736547
Clin Endocrinol (Oxf). 2015 Jul;83(1):1-2
pubmed: 25880812
J Clin Endocrinol Metab. 2009 Aug;94(8):2907-14
pubmed: 19491229
Pituitary. 2021 Feb;24(1):1-13
pubmed: 33079318
Pharm Res. 2014 Aug;31(8):2010-21
pubmed: 24558008
Clin Endocrinol (Oxf). 2012 Jul;77(1):72-8
pubmed: 22066905
Expert Opin Pharmacother. 2021 Aug;22(12):1615-1623
pubmed: 33783289
Neuroendocrinology. 2017;104(3):273-279
pubmed: 27161443
Arch Endocrinol Metab. 2019 Jul 29;63(4):328-336
pubmed: 31365632
Clin Endocrinol (Oxf). 2018 Jun;88(6):889-895
pubmed: 29520805
J Clin Med. 2021 Mar 29;10(7):
pubmed: 33805450
Cancer Chemother Pharmacol. 2019 Feb;83(2):375-385
pubmed: 30535537
Eur J Endocrinol. 2018 Mar;178(3):R89-R100
pubmed: 29339530
Eur J Endocrinol. 2007 Jan;156(1):65-74
pubmed: 17218727
Expert Opin Pharmacother. 2016;17(4):579-88
pubmed: 26808354
Endocrinol Metab (Seoul). 2020 Jun;35(2):206-216
pubmed: 32615705
J Clin Endocrinol Metab. 2015 Jan;100(1):122-31
pubmed: 25250634
J Clin Endocrinol Metab. 1995 Sep;80(9):2768-75
pubmed: 7673422
Pituitary. 2016 Jun;19(3):235-47
pubmed: 26519143
Pituitary. 2017 Feb;20(1):116-120
pubmed: 28197813
Eur J Endocrinol. 2006 Feb;154(2):267-74
pubmed: 16452540